It was a low-key week for the biotech sector with no major updates. Regulatory and pipeline updates from a few players were in focus. Vertex and CRISPR collaborated in 2015 to focus on the use of ...
Sarepta has had ”very robust discussions” with the FDA, company CEO Doug Ingram said Wednesday, speaking during a conference call. The agency has the latest data available from three Phase 1 and 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results